Table 1.
Factor | Experiment Type | Cell Lines | Effects on PD-L1 | Studied Effect |
---|---|---|---|---|
Check point | ||||
Soluble PD-1 [149] | Co-culture and Docetaxel treatment | DU145 and Jurkat | Act. | ↑ Docetaxel resistance |
Soluble factors produced by stromal cells | ||||
AREG [121] | Conditioned medium |
DU145, PC3, LNCaP | ↑ | ↑ Proliferation, migration and invasion |
IL-6 [97] | Conditioned medium |
Dentritic cells | ↑ | // |
Soluble factors produced by adipocytes | ||||
Not identified [136] | Co-culture with conditioned medium |
C4-2 and NK; CWR22Rv1 and NK | ↑ | ↓ NK cytotoxicity |
Soluble factors produced by macrophages | ||||
Not identified [134] | Co-culture with conditioned medium |
C4-2 and NK; CWR22Rv1 and NK | ↑ | ↓ NK cytotoxicity |
Cytokine/Chemokine and
Complement factors |
||||
IL-27 [151] | Treatment | PC3 | ↑ | // |
IFN-γ [10,13,94,103,112,119,128,139,152] | Treatment | PC3 | ↑ | // |
IFN-γ [94] | Treatment | Vcap CWR22Rv1, E006AA | ↑ | // |
IFN-γ [126] | Treatment | TRAMP-C2 | ↑ | // |
IFN-γ [13] | Treatment | LASCPC, NCI-H660 | ↑ | // |
IFN-γ [126] | Treatment | DU145 | = | // |
IFN-γ [13,94,128] | Treatment | LNCaP | = | // |
IFN-γ [94] | Treatment | LAPC-4 | = | // |
IFN-γ [13] | Treatment | BPH1, C4-2, CWRR-1 | = | // |
IFN-γ [10,94,112,119,152] | Treatment | DU145 | ↑ | // |
IFN-γ [112] | Treatment | TRAMP-C2 Ras | ↑ | // |
IFN-γ [106] | Treatment | TRAMP-C1, MyC-CaP | ↑ | // |
Ab anti-IL-6 [134,135,136] | Treatment | C4-2, CWR22Rv1 | ↓ | // |
IL-6 [135] | Treatment | C4-2, CWR22Rv1 | ↑ | // |
IL-17 [145] | Treatment | LNCaP | ↑ | // |
TNF-α [145] | Treatment | LNCaP | ↑ | // |
Chemerin [105] | Treatment of co-culture | DU145 and T | ↓ | ↑ T cytotoxicity |
C5a [18] | Treatment | PC3, C4-2 | ↑ | // |
Hypoxia | ||||
[65] | Co-culture | C4-2 and NK; CWR22Rv1 and NK | ↑ | ↓ NK cytotoxicity |
Act. Activation; ↑ Upregulation; ↓ Downregulation; = No alteration; // No effect was investigated.